BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 30324219)

  • 1. Awakening the "guardian of genome": reactivation of mutant p53.
    Binayke A; Mishra S; Suman P; Das S; Chander H
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Synthetic Approaches towards Small Molecule Reactivators of p53.
    Silva JL; Lima CGS; Rangel LP; Ferretti GDS; Pauli FP; Ribeiro RCB; da Silva TB; da Silva FC; Ferreira VF
    Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
    Garufi A; Pistritto G; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule compounds targeting the p53 pathway: are we finally making progress?
    Yu X; Narayanan S; Vazquez A; Carpizo DR
    Apoptosis; 2014 Jul; 19(7):1055-68. PubMed ID: 24756955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer.
    Miller JJ; Gaiddon C; Storr T
    Chem Soc Rev; 2020 Oct; 49(19):6995-7014. PubMed ID: 32869798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological activation of p53 in cancer cells.
    Athar M; Elmets CA; Kopelovich L
    Curr Pharm Des; 2011; 17(6):631-9. PubMed ID: 21391904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.
    Blanden AR; Yu X; Loh SN; Levine AJ; Carpizo DR
    Drug Discov Today; 2015 Nov; 20(11):1391-7. PubMed ID: 26205328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild type p53 reactivation: from lab bench to clinic.
    Selivanova G
    FEBS Lett; 2014 Aug; 588(16):2628-38. PubMed ID: 24726725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.
    Farnebo M; Bykov VJ; Wiman KG
    Biochem Biophys Res Commun; 2010 May; 396(1):85-9. PubMed ID: 20494116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvation of the fallen angel: Reactivating mutant p53.
    Li Y; Wang Z; Chen Y; Petersen RB; Zheng L; Huang K
    Br J Pharmacol; 2019 Apr; 176(7):817-831. PubMed ID: 30632144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
    Garg S; Singh J; Verma SR
    J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 activation by blocking Snail: a novel pharmacological strategy for cancer.
    Lee SH; Park BJ
    Curr Pharm Des; 2011; 17(6):610-7. PubMed ID: 21391911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
    Wang W; Hu Y
    Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action.
    Wawrzynow B; Zylicz A; Zylicz M
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):161-174. PubMed ID: 29355591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.